Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Regular Articles

Clinicopathological Significance of Epigenetic Inactivation of RASSF1A at 3p21.3 in Stage I Lung Adenocarcinoma

Yoshio Tomizawa, Takashi Kohno, Haruhiko Kondo, Ayaka Otsuka, Michiho Nishioka, Toshiro Niki, Tesshi Yamada, Arafumi Maeshima, Kimio Yoshimura, Ryusei Saito, John D. Minna and Jun Yokota
Yoshio Tomizawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Kohno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haruhiko Kondo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayaka Otsuka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michiho Nishioka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiro Niki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tesshi Yamada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arafumi Maeshima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimio Yoshimura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryusei Saito
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Minna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Yokota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published July 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: July 2002 to April 2021

AbstractFull-text HTMLPDF
Total149433601842

Cited By

Article Information

Volume 8, Issue 7, pp. 2362-2368

PubMed 
12114441

Published By 
American Association for Cancer Research
Print ISSN 
1078-0432
Online ISSN 
1557-3265
History 
  • Received November 29, 2001
  • Revision received April 2, 2002
  • Accepted April 3, 2002
  • Published first July 1, 2002.

Copyright & Usage 
© 2002

Author Information

  1. Yoshio Tomizawa,
  2. Takashi Kohno,
  3. Haruhiko Kondo,
  4. Ayaka Otsuka,
  5. Michiho Nishioka,
  6. Toshiro Niki,
  7. Tesshi Yamada,
  8. Arafumi Maeshima,
  9. Kimio Yoshimura,
  10. Ryusei Saito,
  11. John D. Minna, and
  12. Jun Yokota2
  1. Biology Division [Y. T., T. K., A. O., M. N., J. Y.], Pathology Division [T. N., T. Y., A. M.], and Cancer Information and Epidemiology Division [K. Y.], National Cancer Center Research Institute and Thoracic Surgery Division [H. K.], National Cancer Center Hospital, Tokyo 104-0045, Japan; First Department of Internal Medicine, School of Medicine, University of Gunma, Gunma, 371-8511, Japan [Y. T., R. S.]; and Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390 [J. D. M.]
View Full Text
PreviousNext
Back to top
July 2002
Volume 8, Issue 7
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Clinicopathological Significance of Epigenetic Inactivation of RASSF1A at 3p21.3 in Stage I Lung Adenocarcinoma
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Clinicopathological Significance of Epigenetic Inactivation of RASSF1A at 3p21.3 in Stage I Lung Adenocarcinoma
Yoshio Tomizawa, Takashi Kohno, Haruhiko Kondo, Ayaka Otsuka, Michiho Nishioka, Toshiro Niki, Tesshi Yamada, Arafumi Maeshima, Kimio Yoshimura, Ryusei Saito, John D. Minna and Jun Yokota
Clin Cancer Res July 1 2002 (8) (7) 2362-2368;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Clinicopathological Significance of Epigenetic Inactivation of RASSF1A at 3p21.3 in Stage I Lung Adenocarcinoma
Yoshio Tomizawa, Takashi Kohno, Haruhiko Kondo, Ayaka Otsuka, Michiho Nishioka, Toshiro Niki, Tesshi Yamada, Arafumi Maeshima, Kimio Yoshimura, Ryusei Saito, John D. Minna and Jun Yokota
Clin Cancer Res July 1 2002 (8) (7) 2362-2368;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Regular Articles

  • Intermittent Hypoxia Induces Proteasome-Dependent Down-Regulation of Estrogen Receptor α in Human Breast Carcinoma
  • Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma
  • Ring Finger Protein 43 as a New Target for Cancer Immunotherapy
Show more Regular Articles

Experimental Therapeutics, Preclinical Pharmacology

  • Ring Finger Protein 43 as a New Target for Cancer Immunotherapy
  • 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis
  • A Novel Ex vivo Model System for Evaluation of Conditionally Replicative Adenoviruses Therapeutic Efficacy and Toxicity
Show more Experimental Therapeutics, Preclinical Pharmacology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement